ProNGF is a potential diagnostic biomarker for thyroid cancer.
Identifieur interne : 001E68 ( PubMed/Corpus ); précédent : 001E67; suivant : 001E69ProNGF is a potential diagnostic biomarker for thyroid cancer.
Auteurs : Sam Faulkner ; Severine Roselli ; Yohann Demont ; Jay Pundavela ; Genevieve Choquet ; Philippe Leissner ; Christopher Oldmeadow ; John Attia ; Marjorie M. Walker ; Hubert HondermarckSource :
- Oncotarget [ 1949-2553 ] ; 2016.
Abstract
The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.
DOI: 10.18632/oncotarget.8652
PubMed: 27074571
Links to Exploration step
pubmed:27074571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ProNGF is a potential diagnostic biomarker for thyroid cancer.</title><author><name sortKey="Faulkner, Sam" sort="Faulkner, Sam" uniqKey="Faulkner S" first="Sam" last="Faulkner">Sam Faulkner</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Roselli, Severine" sort="Roselli, Severine" uniqKey="Roselli S" first="Severine" last="Roselli">Severine Roselli</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Demont, Yohann" sort="Demont, Yohann" uniqKey="Demont Y" first="Yohann" last="Demont">Yohann Demont</name><affiliation><nlm:affiliation>Inserm U908, Growth Factor Signaling and Functional Proteomics of Breast Cancer, University of Lille, 59655 Villeneuve d'Ascq, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pundavela, Jay" sort="Pundavela, Jay" uniqKey="Pundavela J" first="Jay" last="Pundavela">Jay Pundavela</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Choquet, Genevieve" sort="Choquet, Genevieve" uniqKey="Choquet G" first="Genevieve" last="Choquet">Genevieve Choquet</name><affiliation><nlm:affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</nlm:affiliation></affiliation></author><author><name sortKey="Leissner, Philippe" sort="Leissner, Philippe" uniqKey="Leissner P" first="Philippe" last="Leissner">Philippe Leissner</name><affiliation><nlm:affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</nlm:affiliation></affiliation></author><author><name sortKey="Oldmeadow, Christopher" sort="Oldmeadow, Christopher" uniqKey="Oldmeadow C" first="Christopher" last="Oldmeadow">Christopher Oldmeadow</name><affiliation><nlm:affiliation>School of Mathematical and Physical Sciences, Faculty of Science and Information Technology, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Attia, John" sort="Attia, John" uniqKey="Attia J" first="John" last="Attia">John Attia</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Marjorie M" sort="Walker, Marjorie M" uniqKey="Walker M" first="Marjorie M" last="Walker">Marjorie M. Walker</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hondermarck, Hubert" sort="Hondermarck, Hubert" uniqKey="Hondermarck H" first="Hubert" last="Hondermarck">Hubert Hondermarck</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27074571</idno><idno type="pmid">27074571</idno><idno type="doi">10.18632/oncotarget.8652</idno><idno type="wicri:Area/PubMed/Corpus">001E68</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">ProNGF is a potential diagnostic biomarker for thyroid cancer.</title><author><name sortKey="Faulkner, Sam" sort="Faulkner, Sam" uniqKey="Faulkner S" first="Sam" last="Faulkner">Sam Faulkner</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Roselli, Severine" sort="Roselli, Severine" uniqKey="Roselli S" first="Severine" last="Roselli">Severine Roselli</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Demont, Yohann" sort="Demont, Yohann" uniqKey="Demont Y" first="Yohann" last="Demont">Yohann Demont</name><affiliation><nlm:affiliation>Inserm U908, Growth Factor Signaling and Functional Proteomics of Breast Cancer, University of Lille, 59655 Villeneuve d'Ascq, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pundavela, Jay" sort="Pundavela, Jay" uniqKey="Pundavela J" first="Jay" last="Pundavela">Jay Pundavela</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Choquet, Genevieve" sort="Choquet, Genevieve" uniqKey="Choquet G" first="Genevieve" last="Choquet">Genevieve Choquet</name><affiliation><nlm:affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</nlm:affiliation></affiliation></author><author><name sortKey="Leissner, Philippe" sort="Leissner, Philippe" uniqKey="Leissner P" first="Philippe" last="Leissner">Philippe Leissner</name><affiliation><nlm:affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</nlm:affiliation></affiliation></author><author><name sortKey="Oldmeadow, Christopher" sort="Oldmeadow, Christopher" uniqKey="Oldmeadow C" first="Christopher" last="Oldmeadow">Christopher Oldmeadow</name><affiliation><nlm:affiliation>School of Mathematical and Physical Sciences, Faculty of Science and Information Technology, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Attia, John" sort="Attia, John" uniqKey="Attia J" first="John" last="Attia">John Attia</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Walker, Marjorie M" sort="Walker, Marjorie M" uniqKey="Walker M" first="Marjorie M" last="Walker">Marjorie M. Walker</name><affiliation><nlm:affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hondermarck, Hubert" sort="Hondermarck, Hubert" uniqKey="Hondermarck H" first="Hubert" last="Hondermarck">Hubert Hondermarck</name><affiliation><nlm:affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27074571</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>18</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1949-2553</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>19</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Oncotarget</Title><ISOAbbreviation>Oncotarget</ISOAbbreviation></Journal><ArticleTitle>ProNGF is a potential diagnostic biomarker for thyroid cancer.</ArticleTitle><Pagination><MedlinePgn>28488-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.8652</ELocationID><Abstract><AbstractText>The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faulkner</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roselli</LastName><ForeName>Severine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demont</LastName><ForeName>Yohann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Inserm U908, Growth Factor Signaling and Functional Proteomics of Breast Cancer, University of Lille, 59655 Villeneuve d'Ascq, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Present address: INSERM U1138 team 11, Centre de Recherche des Cordeliers, 75006 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pundavela</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choquet</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leissner</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l'Etoile, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldmeadow</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Mathematical and Physical Sciences, Faculty of Science and Information Technology, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attia</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health & Medicine, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Marjorie M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health & Medicine, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hondermarck</LastName><ForeName>Hubert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncotarget</MedlineTA><NlmUniqueID>101532965</NlmUniqueID><ISSNLinking>1949-2553</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Development. 2013 May;140(10):2108-17</RefSource><PMID Version="1">23633509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Invest Dermatol. 2008 Aug;128(8):2031-40</RefSource><PMID Version="1">18305571</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Endocrinol Invest. 2010;33(5 Suppl):51-6</RefSource><PMID Version="1">20543551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Genet. 2012 Mar 13;13(4):227-32</RefSource><PMID Version="1">22411467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stem Cells. 2015 Feb;33(2):342-53</RefSource><PMID Version="1">25286822</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Anticancer Ther. 2008 Sep;8(9):1399-413</RefSource><PMID Version="1">18759692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Sep 18;513(7518):382-7</RefSource><PMID Version="1">25043054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thyroid. 2009 Nov;19(11):1167-214</RefSource><PMID Version="1">19860577</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2000 Nov 23;19(50):5729-35</RefSource><PMID Version="1">11126359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2010 Nov;8(11):1228-74</RefSource><PMID Version="1">21081783</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2012 Apr;35(4):261-70</RefSource><PMID Version="1">22341525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Pathol. 2006 May;37(5):562-8</RefSource><PMID Version="1">16647954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 2009 Jan;150(1):509-18</RefSource><PMID Version="1">18687776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2013 Mar;13(3):184-99</RefSource><PMID Version="1">23429735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2000 Mar;6(3):1093-103</RefSource><PMID Version="1">10741739</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Endocrinol. 2010 May 28;321(1):44-9</RefSource><PMID Version="1">19883730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 1998 Jan;4(1):223-8</RefSource><PMID Version="1">9516975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thyroid. 1995 Feb;5(1):67-73</RefSource><PMID Version="1">7787437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2001 Nov 30;294(5548):1945-8</RefSource><PMID Version="1">11729324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2004 May;89(3):581-92</RefSource><PMID Version="1">15086515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2014 Dec;184(12):3156-62</RefSource><PMID Version="1">25285721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Biol Regul. 2015 May;58:16-27</RefSource><PMID Version="1">25491371</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2012 Jan 13;287(3):1923-31</RefSource><PMID Version="1">22128158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource><PMID Version="1">23000897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2012 May;2(5):401-4</RefSource><PMID Version="1">22588877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2009 Jul 3;284(27):18424-33</RefSource><PMID Version="1">19389705</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2004 Sep 23;23(44):7436-40</RefSource><PMID Version="1">15273715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Biol. 1999 Mar;19(3):1720-30</RefSource><PMID Version="1">10022859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2004 Feb 26;427(6977):843-8</RefSource><PMID Version="1">14985763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4540-5</RefSource><PMID Version="1">10200298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2008 Nov;107(4):1124-35</RefSource><PMID Version="1">18808449</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diagnostic biomarker</Keyword><Keyword MajorTopicYN="N">growth factors</Keyword><Keyword MajorTopicYN="N">proNGF</Keyword><Keyword MajorTopicYN="N">thyroid cancer</Keyword></KeywordList><CoiStatement>HH, YD and GC are inventors on patent US 20130171173 A1 “Method for proNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of proNGF”.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27074571</ArticleId><ArticleId IdType="pmc">PMC5053740</ArticleId><ArticleId IdType="pii">8652</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.8652</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27074571
|texte= ProNGF is a potential diagnostic biomarker for thyroid cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27074571" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |